ReviewCurrent opinion in HIV and AIDS2010
Is developing an HIV-1 vaccine possible?
Review in Current opinion in HIV and AIDS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.AIDS research and human retroviruses · 2012Trial
- Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.PLoS pathogens · 2015Article
- Progress in HIV-1 vaccine development.The Journal of allergy and clinical immunology · 2014Review
- Which Antibody Functions are Important for an HIV Vaccine?Frontiers in immunology · 2014Review
- Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention.Current HIV research · 2013Article
- HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.Journal of virology · 2012Article
- The design and evaluation of HIV-1 vaccines.AIDS (London, England) · 2012Review
- Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection.Journal of virology · 2012Article
- B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.Nature biotechnology · 2012Article
- Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.AIDS research and human retroviruses · 2012Article
- Article
- Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.Journal of AIDS & clinical research · 2012Article
- Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.Journal of virology · 2011Article
- An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.Journal of virology · 2011Article
- Acute HIV-1 Infection.The New England journal of medicine · 2011Review
- Cloning, expression and preliminary crystallographic analysis of the equine infectious anaemia virus (EIAV) gp45 ectodomain.Acta crystallographica. Section F, Structural biology and crystallization communications · 2011Article
- B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Trends in molecular medicine · 2011Article
- Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success. RECENT
findingsPassive protection studies, with broad neutralizing antibodies for mucosal simian-HIV challenges, in nonhuman primates have suggested that lower doses of neutralizing antibodies than previously thought may be effective in preventing HIV-1 infection. The use of recombinant antibody technology coupled with the ability to culture single memory B cells has yielded new broad neutralizing antibodies and new targets for vaccine design. The success of the RV144 Thai HIV-1 efficacy trials with a replication-defective recombinant canarypox vector (ALVAC)/gp120 prime, clade B/E recombinant gp120 protein boost showing 31% efficacy has given hope that indeed a protective HIV-1 vaccine can be made. SUMMARY: Recent data in the last year have provided new hope that a clinically useful preventive HIV-1 vaccine can potentially be made. The path forward will require development of improved immunogens, understanding the correlates of protection to HIV-1, and development of immunogens to induce antibodies that can prevent the initial stages of HIV-1 infection at mucosal sites, in order to improve on the RV144 trial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.